QI Ran,NIE Xuyang,LIU Xuting,et al.Pharmacoeconomic evaluation of serplulimab combined with chemotherapy regimens for the first-line treatment of extensive-stage small-cell lung cancer[J].ZHONGGUO YAOFANG,2023,34(11):1368-1373.
QI Ran,NIE Xuyang,LIU Xuting,et al.Pharmacoeconomic evaluation of serplulimab combined with chemotherapy regimens for the first-line treatment of extensive-stage small-cell lung cancer[J].ZHONGGUO YAOFANG,2023,34(11):1368-1373. DOI: 10.6039/j.issn.1001-0408.2023.11.16.
Pharmacoeconomic evaluation of serplulimab combined with chemotherapy regimens for the first-line treatment of extensive-stage small-cell lung cancer
To evaluate the economics of serplulimab combined with chemotherapy regimens for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) from the perspective of health system in China.
METHODS
2
A partitioned survival model was constructed based on the ASTRUM-005 clinical trial and related literature data, with a model simulation time frame of 10 years and a 3-week cycle, and both cost and utility values were discounted using a 5% discount rate. The quality-adjusted life year (QALY) was used as a model output indicator and the incremental cost-effectiveness ratio (ICER) was calculated to evaluate the economics of serplulimab combined with chemotherapy regimens (serplulimab group) versus chemotherapy alone regimens (chemotherapy alone group) for the first-line treatment of ES-SCLC. One-way sensitivity analysis and probabilistic sensitivity analysis were used to verify the robustness of the results of the base-case analysis and to conduct a scenario analysis for the serplulimab patient assistance program.
RESULTS
2
The results of the base-case analysis showed that compared with chemotherapy alone group, ICER of serplulimab group was 758 690.27 yuan/QALY, which was higher than 3 times China’s per capita gross domestic product (GDP) in 2022 as the willingness-to-pay (WTP) threshold. The results of the scenario analysis showed that compared with chemotherapy alone group, the ICER of serplulimab group was 172 275.74 yuan/QALY, which was below above WTP threshold. The one-way sensitivity analysis showed that the progress-free survival utility value, serplulimab price and so on had a significant impact on the model results. The results of the probabilistic sensitivity analysis showed that the probability of the serplulimab group being economic was 0 when the serplulimab patient assistance program was not considered, but 100% when the patient assistance program was considered.
CONCLUSIONS
2
At a WTP threshold of 3 times China’s per capita GDP in 2022, the serplulimab group is no cost-effectiveness compared to the chemotherapy alone group; however, this result is reversed when the patient assistance program is taken into account.
关键词
斯鲁利单抗广泛期小细胞肺癌一线化疗方案分区生存模型成本-效用分析药物经济学
Keywords
extensive-stage small cell lung cancerfirst-line chemotherapypartitioned survival modelcost-utility analysispharmacoeconomics
references
SUNG H,FERLAY J,SIEGEL R L,et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3):209-249.
ZHENG R S,ZHANG S W,ZENG H M,et al. Cancer incidence and mortality in China,2016[J]. J Natl Cancer Cent,2022,2(1):1-9.
WANG S C,TANG J J,SUN T T,et al. Survival changes in patients with small cell lung cancer and disparities between different sexes,socioeconomic statuses and ages[J]. Sci Rep,2017,7(1):1339.
SIEGEL R L,MILLER K D,JEMAL A. Cancer statistics,2015[J]. CA,2015,65(1):5-29.
FRÜH M,DE RUYSSCHER D,POPAT S,et al. Small-cell lung cancer (SCLC):ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up[J]. Ann Oncol,2013,24(Suppl 6):vi99-vi105.
JONES G S,ELIMIAN K,BALDWIN D R,et al. A systematic review of survival following anti-cancer treatment for small cell lung cancer[J]. Lung Cancer,2020,141:44-55.
SHAO T H,ZHAO M Y,LIANG L Y,et al. Serplulimab plus chemotherapy vs chemotherapy for treatment of US and Chinese patients with extensive-stage small-cell lung cancer:a cost-effectiveness analysis to inform drug pricing[J/OL]. Bio Drugs,2023[2023-05-01]. https://pubmed.ncbi.nlm.nih.gov/36840914/#full-view-affiliation-2https://pubmed.ncbi.nlm.nih.gov/36840914/#full-view-affiliation-2. DOI:10.1007/s40259-023-00586-6http://dx.doi.org/10.1007/s40259-023-00586-6.
CHENG Y,HAN L,WU L,et al. Effect of first-line serp- lulimab vs. placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer:the ASTRUM-005 randomized clinical trial[J]. JAMA,2022,328(12):1223-1232.
GALLACHER D,AUGUSTE P,CONNOCK M. How do pharmaceutical companies model survival of cancer patients? A review of NICE single technology appraisals in 2017[J]. Int J Technol Assess Health Care,2019,35(2):160-167.
DING D,HU H,LI S,et al. Cost-effectiveness analysis of durvalumab plus chemotherapy in the first-line treatment of extensive-stage small cell lung cancer[J]. J Natl Compr Canc Netw,2021,19(10):1141-1147.
YANG S C,KUO C W,LAI W W,et al. Dynamic changes of health utility in lung cancer patients receiving different treatments:a 7-year follow-up[J]. J Thorac Oncol,2019,14(11):1892-1900.
ZHU Y,LIU K,QIN Q,et al. Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer:a cost-effectiveness analysis[J]. Front Immunol,2022,13:1044678.
Cost-utility analysis of sintilimab combined with chemotherapy in first-line treatment of advanced, recurrent or metastatic esophageal squamous cell carcinoma
Cost-utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in the second-line treatment for HER2-positive metastatic breast cancer
Pharmacoeconomics of ivabradine in the treatment of CHF in the context of “Quadruple Therapy”
Study on pharmacoeconomic evaluation of vericiguat in the treatment of heart failure with reduced ejection fraction
Pharmacoeconomic evaluation of sugemalimab consolidation therapy for stage Ⅲ non-small cell lung cancer
Related Author
CHEN Qiuping
SHAO Mingyi
ZHANG Rongrong
CHEN Xiaoqi
WU Yanan
WU Fang
HOU Yanhong
CHEN Congling
Related Institution
First College of Clinical Medicine, Henan University of Chinese Medicine
Dept. of Gastroenterology, the First Affiliated Hospital of Henan University of Chinese Medicine
School of International Pharmaceutical Business, China Pharmaceutical University
Dept. of Pharmacy, Nanjing Drum Tower Hospital
School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University